Clinical Trial Update: Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial testing compound sodium alginate oral suspension for symptomatic relief in gastroesophageal reflux disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Reflux Disease

Drugs mentioned

• Sodium alginate oral suspension (sodium alginate)

Snippet

Sponsor: Reckitt Benckiser Healthcare (UK) Limited | Conditions: Gastro-esophageal Reflux Disease (GERD) | Phase 3 | Status: COMPLETED